Deliberate AI

Deliberate AI operates at the intersection of mental-health diagnostics, clinical-trial technology, and ambient healthcare intelligence. Its stated focus differs from consumer behavioral-health platforms because the company emphasizes clinical research and drug-development workflows, including an AI-COA™ model accepted into the FDA’s ISTAND pilot in January 2024. It also differs from general-purpose ambient documentation companies by combining clinical workflow support with multimodal biomarker discovery and CNS-focused assessment. The product set includes Multitude™, a platform for extracting behavioral and physiological features from video, an ambient clinical intelligence platform, and a multimodal biomarker development platform. Deliberate AI’s differentiation is therefore best understood as the combination of computational psychiatry, facial-expression and prosody analysis, clinical-trial applicability, and therapy-process measurement. Its small, New York-based team and seed-stage status indicate an emerging specialist rather than a scaled category leader.

Deliberate AI’s trajectory shows a progression from early-stage formation in 2020 toward increasingly formalized clinical and research applications. The company recorded an initial grant in September 2020 and a seed round in March 2021 involving four investors, followed by non-equity assistance in July 2022 from StartX and PharmStars. Grants in July 2023 and September 2024 expanded the non-dilutive component of its financing history; the September 2024 grant is listed at $20 million, which accounts for the company’s stated total funding. The major product and validation inflection point came in January 2024, when AI-COA™ entered the FDA’s ISTAND pilot for depression and anxiety assessment. By February 2025, Deliberate AI had added a seed round led by One Mind Accelerator, suggesting continued investor engagement after the regulatory milestone, although no amount was disclosed. The current team count is five featured positions, including four founders and a senior data scientist. With no reported layoffs and no disclosed hiring acceleration, growth appears research-led and milestone-driven rather than workforce-led.